Percutaneous Interventions Alter the Hemostatic Profile of Patients With Unstable Versus Stable Angina  by Yazdani, Shahram et al.
Percutaneous Interventions Alter the Hemostatic Profile of Patients
With Unstable Versus Stable Angina
SHAHRAM YAZDANI, MD,*† ALAN D. SIMON, MD,* LANCE KOVAR, MD,*
WEIZHENG WANG, MD,* ALLAN SCHWARTZ, MD, FACC,* LEROY E. RABBANI, MD, FACC*
New York and Roslyn, New York
Objectives. The objectives of this study were to define the
hemostatic profiles of patients with unstable angina compared
with patients with stable angina and to investigate the effect of
percutaneous interventions on the follow-up hemostatic profiles of
these patients.
Background. Disturbances in hemostatic factors have been
shown to be present in various clinical syndromes involving
coronary artery disease. However, their role in stable angina
versus unstable angina is less well defined.
Methods. We studied 61 patients with either stable or unstable
angina undergoing percutaneous coronary interventions. Blood
samples were drawn immediately before the intervention and at
1-month follow-up. Plasma levels of tissue-type plasminogen
activator (t-PA), plasminogen activator inhibitor-1 (PAI-1) and
von Willebrand factor (vWF) were measured by enzyme-linked
immunosorbent assays.
Results. Patients with unstable angina had significantly higher
t-PA levels (mean [6SE] 23.7 6 3.4 vs. 14.3 6 1.4 ng/ml,
respectively, p 5 0.02) and vWF antigen concentrations (2,231 6
157 vs. 1,792 6 108 mU/ml, respectively, p 5 0.03) than patients
with stable angina. No statistically significant differences were
observed in the PAI-1 levels between the two groups (27.9 6 5.5 vs.
21.4 6 2.5 ng/ml, respectively, p 5 0.25). At 1-month follow-up,
there were no longer any significant differences in the t-PA or vWF
levels between the two groups (15.7 6 1.2 vs. 13.6 6 0.6 ng/ml, p 5
0.13; 1,962 6 170 vs. 1,809 6 88 mU/ml, p 5 0.39, respectively).
There were no significant differences between the hemostatic
profiles of patients undergoing percutaneous transluminal coro-
nary angioplasty or coronary stenting initially and at 1-month
follow-up.
Conclusions. These data suggest that elevated plasma levels of
t-PA and vWF may correlate with instability of atheromatous
plaques, and that their decrease after coronary interventions may
reflect plaque reendothelialization and stabilization.
(J Am Coll Cardiol 1997;30:1284–7)
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Disturbances in the fibrinolytic system have been implicated in
the pathogenesis and development of coronary artery disease
(1,2). However, studies comparing the fibrinolytic profiles of
patients with unstable angina to those with stable angina have
shown conflicting results. Although some studies have shown
levels of various factors to be more elevated in patients with
unstable angina (3,4), others have shown no differences in the
levels of these factors between patients with unstable angina
and those with stable angina (5). Furthermore, there is scant
data on the effect of percutaneous coronary interventions on
the fibrinolytic system in patients with coronary artery disease.
We hypothesized that patients with unstable angina would
have different hemostatic profiles from patients with stable
angina and that successful percutaneous coronary interven-
tions might alter these profiles. In this study, we demonstrate
that the levels of tissue-type plasminogen activator (t-PA) and
von Willebrand factor (vWF) antigens are higher in patients
with unstable angina compared with those with stable angina,
although there is no significant difference in the levels of
plasminogen activator inhibitor-1 (PAI-1) antigen between the
two groups. Furthermore, we demonstrate that, after success-
ful percutaneous intervention by either balloon angioplasty or
coronary stent placement, there is no longer any significant
difference in the levels of t-PA and vWF antigens between the
two groups.
Methods
This study was undertaken after approval by the Institu-
tional Review Boards at Columbia–Presbyterian Medical Cen-
ter and St. Francis Hospital.
Patient selection. Between July 1995 and April 1996, pa-
tients referred for percutaneous interventions to the cardiac
catheterization laboratories at the participating hospitals were
approached for enrollment in the study. A total of 61 patients
were included in the study. Written, informed consent was
obtained from all patients before their participation. Periph-
eral blood was withdrawn once at the start of the procedure
From the Division of Cardiology, Department of Medicine, *Columbia–
Presbyterian Medical Center, New York and †Saint Francis Hospital, Roslyn,
New York. This study was supported by Physician Scientist Award No. K11-
HL02578 (Dr. Rabbani), from the National Heart, Lung, and Blood Institute,
National Institutes of Health, Bethesda, Maryland and by the Sol and Margaret
Berger Foundation, Clifton, New Jersey (Dr. Rabbani).
Manuscript received March 10, 1997; revised manuscript received July 1,
1997, accepted July 9, 1997.
Address for correspondence: Dr. LeRoy E. Rabbani, Division of Cardiology,
Department of Medicine, Columbia University College of Physicians and
Surgeons, 630 West 168th Street, New York, New York 10032.
JACC Vol. 30, No. 5
November 1, 1997:1284–7
1284
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00275-1
before heparin was given and again at 1-month follow-up.
Seven patients were lost to follow-up, and these patients were
excluded from the final analysis.
Exclusion criteria. Patients with a history of myocardial
infarction documented by enzyme elevation within the previ-
ous 4 weeks were excluded. All patients with suspected hemo-
static disorders, malignancy or inflammatory conditions were
excluded.
Patient stratification. Patients were stratified to two
groups based on their clinical presentation: 1) patients pre-
senting with at least one episode of pain at rest lasting ,20 min
and associated with electrocardiographic changes and no evi-
dence of myocardial infarction were classified as having unsta-
ble angina; and 2) patients with chronic exertional pain and no
episodes of rest angina who were referred for elective angio-
plasty were classified as having stable angina.
Medications. After the procedure, each patient’s medical
regimen was determined by the referring cardiologist. How-
ever, all patients who had percutaneous transluminal coronary
angioplasty (PTCA) received 325 mg of aspirin daily for at
least 1 month, whereas patients with coronary stents received
either 75 mg of dipyridamole three times a day, 325 mg of
aspirin daily plus warfarin (Coumadin) or 325 mg of aspirin
daily plus 250 mg of ticlopidine twice a day for 1 month.
Blood samples. The initial blood sample was withdrawn
from the venous sheath before the start of the coronary
intervention. The follow-up samples were obtained by veni-
puncture from the patients’ forearm at 1 month. Each time
30 ml of blood was collected and divided into 10-ml tubes
containing 1 ml of 3.13% sodium citrate. The plasma was
separated by centrifugation at 3,000 rpm for 15 min and frozen
at 270° until it was assayed for hemostatic factors.
Hemostatic system. The concentrations of t-PA, PAI-1 and
vWF antigens were measured by commercially available im-
munoassay kits (American Diagnostica), as previously de-
scribed (6).
Statistics. Patients were divided into two groups for anal-
ysis: those with unstable angina and those with stable angina.
Baseline characteristics of the patients were compared using
the unpaired t test for continuous variables and the chi-square
test for discrete variables. The significance of the correlation
between t-PA and vWF levels and cholesterol was measured
using the z test. Because the data were not distributed nor-
mally, the Mann-Whitney U test was used to compare t-PA,
PAI-1 and vWF antigens between the two groups. The Mann-
Whitney U test was also used to compare hemostatic factors in
patients who had PTCA versus coronary stent placement.
Results are expressed as mean 6 SE. Statistical significance
was defined as p , 0.05.
Results
The differences in the baseline characteristics between the
two groups are presented in Table 1. Patients with unstable
angina were more likely to be taking heparin or nitroglycerin.
Patients with unstable angina also had higher cholesterol
levels. The initial and 1-month follow-up values of the plasma
hemostatic factors are shown in Table 2. The mean value of the
t-PA antigen levels was higher in patients with unstable angina
compared with patients with stable angina at the time of the
percutaneous intervention (mean [6SE] 23.7 6 3.4 vs. 14.3 6
Abbreviations and Acronyms
PAI-1 5 plasminogen activator inhibitor-1
PTCA 5 percutaneous transluminal coronary angioplasty
t-PA 5 tissue-type plasminogen activator
vWF 5 von Willebrand factor
Table 1. Baseline Clinical Characteristics of Patients With Stable
and Unstable Angina
Unstable
Angina
(n 5 18)
Stable
Angina
(n 5 43)
p
Value*
Age (yr) 60 6 13 62 6 9 NS
Gender (M/F) 14/4 38/5 NS
Risk factors
Hypertension 13 (72) 31 (72) NS
Smoking 3 (17) 7 (16) NS
Diabetes 7 (39) 10 (23) NS
Hyperlipidemia 12 (67) 23 (53) NS
Medications
Aspirin 18 (100) 43 (100) NS
Beta-blocker 10 (56) 29 (67) NS
Heparin 11 (61) 10 (23) 0.005
ACE inhibitor 6 (33) 8 (19) NS
Nitroglycerin 13 (72) 13 (27) 0.003
Low EF, ,40% 7 (39) 8 (19) NS
WBC (109/liters) 8 6 1.7 9 6 2 NS
Multivessel disease 6 (33) 14 (33) NS
Cholesterol (mg/dl) 216 6 50 193 6 38 0.05
Triglycerides (mg/dl) 207 6 107 191 6 126 NS
*Unstable versus stable angina. Data are presented as mean value 6 SD or
number (%) of patients. ACE 5 angiotensin-converting enzyme; EF 5 ejection
fraction; NS 5 not significant; WBC 5 white blood cell count.
Table 2. Values of Tissue-Type Plasminogen Activator, von
Willebrand Factor and Plasminogen Activator Inhibitor-1 in Patients
With Stable Versus Unstable Angina
Unstable Angina Stable Angina p Value
Initial values
t-PA (ng/ml) 23.7 6 3.4 14.3 6 1.4 0.02
vWF (mU/ml) 2,231 6 157 1,792 6 108 0.03
PAI-1 (ng/ml) 27.9 6 5.5 21.4 6 2.5 NS
Follow-up values
t-PA (ng/ml) 15.7 6 1.2 13.6 6 0.6 NS
vWF (mU/ml) 1,962 6 170 1,809 6 88 NS
PAI-1 (ng/ml) 31.6 6 5.7 29.4 6 3.3 NS
Data are expressed as mean value 6 SE. NS 5 not significant; PAI-1 5
plasminogen activator inhibitor-1; t-PA 5 tissue-type plasminogen activator;
vWF 5 von Willebrand factor.
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1.4 ng/ml). The mean value of vWF antigen levels was also
higher in patients with unstable angina compared with patients
with stable angina (2,231 6 157 vs. 1,792 6 108 mU/ml). The
difference between the unstable angina and stable angina
groups was significant for t-PA (p 5 0.02) as well as for vWF
(p 5 0.03). However, there were no significant differences in
the PAI-1 antigen levels between the two groups (27.9 6 5.5 vs.
21.4 6 2.5 ng/ml, p 5 0.25). When cholesterol levels were
compared with t-PA and vWF antigen levels, no significant
correlation was demonstrated (data not shown).
At 1-month follow-up, there were no longer any significant
differences in the values of t-PA between the unstable angina
and stable angina groups (15.7 6 1.2 vs. 13.6 6 0.6 ng/ml,
respectively, p 5 0.13). The values of vWF were also no longer
significantly different between the unstable and stable angina
groups (1,962 6 170 vs. 1,809 6 88 mU/ml, respectively, p 5
0.39). At the time of 1-month follow-up, 12 patients had
recurrent angina (3 with unstable angina and 9 with stable
angina).
The values of hemostatic factors in patients receiving
coronary stents (n 5 27) were compared with those of patients
who underwent PTCA only (n 5 34). Twenty-two patients with
stable angina had PTCA, whereas 21 patients had coronary
stent placement. Among patients with unstable angina, 11 had
PTCA and 7 received coronary stents. The initial and
follow-up values of hemostatic factors in these patients are
shown in Table 3. There were no differences in any of the
hemostatic factors in the study patients based on the type of
percutaneous coronary intervention used.
Discussion
We determined the levels of t-PA, PAI-1 and vWF antigens
in patients with unstable and stable angina undergoing coro-
nary angiography and percutaneous coronary interventions.
There were significant elevations of t-PA and vWF antigen
levels in patients with unstable angina compared with those
with stable angina. However, no significant differences were
observed in the PAI-1 antigen levels between the two groups.
Furthermore, we monitored these patients 1 month after
percutaneous coronary interventions and demonstrated for the
first time that, after successful intervention with either PTCA
or coronary stent placement, there were no longer any differ-
ences between the levels of t-PA and vWF antigens between
the two groups.
von Willebrand factor in angina pectoris. This factor is
synthesized by endothelial cells and megakaryocytes (7,8). It is
essential both for platelet adhesion and aggregation. Insults to
endothelial integrity result in release of vWF into the blood.
Disease processes involving endothelial cell injury have been
shown to have elevated levels of vWF (9). Unstable angina is
the result of plaque rupture and subsequent exposure of the
subendothelial contents to the blood (10). As plaques rupture,
the damaged endothelial cells release vWF, which may account
for the elevated vWF antigen levels in this study. It has also
been demonstrated that vWF levels are increased in conditions
involving intravascular clot formation (11). Therefore, elevated
levels of vWF in our study could also be a marker of thrombus
formation at the site of plaque rupture.
Tissue-type plasminogen activator in angina pectoris. El-
evated serum t-PA levels have been demonstrated in cardio-
vascular conditions involving endothelial cell damage (12).
Levels of t-PA are also increased in conditions involving
intravascular thrombus formation (13). In unstable angina,
elevated t-PA antigen levels may be the result of endothelial
cell damage and thrombus formation at the site of plaque
rupture. Elevated levels of t-PA antigen might seem paradoxic
at first. However, most of the t-PA in the plasma travels while
bound to PAI-1 molecules (14). As such, the increased t-PA
levels reflect circulating t-PA–PAI-1 complexes that are inac-
tive and therefore markers of attenuated rather than enhanced
fibrinolytic activity (15).
Effect of percutaneous coronary interventions on hemo-
static factors. We observed that after balloon angioplasty or
stent placement, the levels of t-PA and vWF were no longer
distinguishable between the two groups. In the pig model of
balloon angioplasty, regrowth of endothelium over the injury
site is complete 7 days after the procedure (16). It has also
been demonstrated in swine models of stent placement that
stents are completely covered by regenerated endothelium 28
days after stent deployment (17,18). As healthy endothelium
covers the plaque region, it is reasonable to postulate that t-PA
and vWF antigen levels should decrease. Therefore, the atten-
uation of these factors after the intervention in the unstable
angina group could reflect reemergence of healthy endothe-
lium as well as plaque stabilization and quiescence.
Conclusions. Serum levels of t-PA and vWF antigens are
elevated in patients with unstable angina compared with those
with stable angina. These differences are no longer present 1
month after a successful percutaneous coronary intervention—
either balloon angioplasty or coronary stent placement—which
may represent plaque reendothelialization as well as stabiliza-
tion.
Table 3. Values of Tissue-Type Plasminogen Activator, von
Willebrand Factor and Plasminogen Activator Inhibitor-1 in
Patients Receiving Stents Versus Percutaneous Transluminal
Coronary Angioplasty*
Coronary Stents
(n 5 27)
PTCA
(n 5 34)
Initial values
t-PA (ng/ml) 14.5 6 2.0 19.2 6 2.1
vWF (mU/ml) 1,933 6 133 1,912 6 129
PAI-1 (ng/ml) 22.2 6 3.0 24.1 6 3.5
Follow-up values
t-PA (ng/ml) 15.3 6 0.8 13.3 6 0.8
vWF (mU/ml) 1,855 6 144 1,853 6 84
PAI-1 (ng/ml) 33.1 6 4.6 27.7 6 3.5
*p 5 NS for all comparisons. Data are expressed as mean value 6 SE.
PTCA 5 percutaneous transluminal coronary angioplasty; other abbreviations as
in Table 2.
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